| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10052927 | The Journal of Urology | 2005 | 5 Pages |
Abstract
No significant difference in CR rates could be demonstrated with intravesical instillations of epirubicin or BCG. Time to recurrence was significantly longer in patients treated with BCG after having achieved a CR. More CIS recurrences were found in patients treated with epirubicin. For time to progression and survival longer followup is warranted. Side effects were more frequent in patients on BCG.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
THEO M. de REIJKE, KARL HEINZ KURTH, RICHARD J. SYLVESTER, REG R. HALL, MAURIZIO BRAUSI, KEES van de BEEK, K.E.J. LANDSOGHT, PAUL CARPENTIER,